glp-1 prostate cancer Targeting obesity, metabolic syndrome, and cancer: agonists as emerging therapeutic agents | Discover Oncology Forced expression of glucagon‐like peptide‐1

(2025) 23:71525.e3

Application Aside from their benefits for the treatment of type 2 diabetes and obesity, GLP-1 based drugs are beginning to be approved for the treatment of other conditions

Soleiman designs GLP1 agonist protocols, including eligibility criteria, dose-escalation schedules, and follow-up intervals, rather than relying on generic weight-loss program templates

Enhances insulins action on muscle cells and helps keep blood glucose levels low while aiding in glycogen repletion

Shakoor, H

Furthermore, stress causes CRH release from hypothalamus into the pituitary gland and releases adrenocorticotropic hormone (ACTH) from the pituitary gland